 |
|
The Severity of Myasthenia Gravis Correlates With the Serum Concentration of Titin and Ryanodine Receptor Antibodies
Fredrik Romi, MD;
Geir Olve Skeie, MD;
Johan A. Aarli, MD;
Nils Erik Gilhus, MD
Arch Neurol. 2000;57:1596-1600.
Background Myasthenia gravis (MG) is caused by autoantibodies to the acetylcholine receptor (AChR). Non-AChR muscle autoantibodies are present in many MG serum samples, mainly from patients with thymoma or late-onset MG. The exact relationship between MG severity and several non-AChR muscle antibodies is unknown.
Objective To study the correlation between the severity of MG and the concentration of antibodies against striated muscle tissue sections, titin, citric acid antigen, ryanodine receptor, and AChR.
Setting The severity of MG was graded in 146 consecutive patients with MG, and their serum samples were tested for the presence of autoantibodies. Ten patients who were titin antibody positive were observed in longitudinal follow-up.
Results No significant difference was found in MG severity between late-onset and thymoma MG. Titin, citric acid antigen, and ryanodine receptor antibodies occurred significantly more often among patients with severe MG than among patients with less severe disease. Changes in MG severity correlated with changes in titin antibody titer in the individual patient. Titin antibodies showed a better longitudinal correlation with disease severity than the AChR antibodies.
Conclusions Non-AChR muscle autoantibodies occurred more frequently in severe MG regardless of MG subgroup. Thymoma per se does not generate a more severe MG. It may well be the presence of a humoral immune response to non-AChR muscle antigens such as titin, citric acid antigen, and ryanodine receptor that leads to a severe disease, not the presence of thymoma or a late age of onset. These antibodies can serve as important prognostic markers in MG regardless of the presence of thymoma.
The Department of Neurology, Haukeland University Hospital, Bergen, Norway.
RELATED ARTICLE
Archives of Neurology Reader's Choice: Continuing Medical Education
Arch Neurol. 2000;57(11):1661-1662.
FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Neuromyelitis optica immunoglobulins as a marker of disease activity and response to therapy in patients with neuromyelitis optica
Weinstock-Guttman et al.
Mult Scler 2008;14:1061-1067.
ABSTRACT
Polygenic Disease Associations in Thymomatous Myasthenia Gravis
Amdahl et al.
Arch Neurol 2007;64:1729-1733.
ABSTRACT
| FULL TEXT
Classification of Myasthenia Gravis Based on Autoantibody Status
Suzuki et al.
Arch Neurol 2007;64:1121-1124.
ABSTRACT
| FULL TEXT
Striational Antibodies in Myasthenia Gravis: Reactivity and Possible Clinical Significance
Romi et al.
Arch Neurol 2005;62:442-446.
ABSTRACT
| FULL TEXT
Treatment of autoimmune myasthenia gravis
Richman and Agius
Neurology 2003;61:1652-1661.
ABSTRACT
| FULL TEXT
The immunologic role of thymectomy in the treatment of myasthenia gravis: implication of thymus-associated B-lymphocyte subset in reduction of the anti-acetylcholine receptor antibody titer
Okumura et al.
J. Thorac. Cardiovasc. Surg. 2003;126:1922-1928.
ABSTRACT
| FULL TEXT
Disorders of the Respiratory Muscles
Laghi and Tobin
Am. J. Respir. Crit. Care Med. 2003;168:10-48.
ABSTRACT
| FULL TEXT
The occurrence of anti-titin antibodies and thymomas: A population survey of MG 1970-1999
Somnier and Engel
Neurology 2002;59:92-98.
ABSTRACT
| FULL TEXT
|
